Results 1 to 10 of about 15,339 (211)
Refractory tardive dyskinesia in the critical care setting: A case report of successful use of phenobarbital [PDF]
SAGE Open Medical Case ReportsTardive dyskinesia is a hyperkinetic movement disorder most often induced by chronic antipsychotic use. It can be challenging to treat, particularly when symptoms persist despite standard therapies such as vesicular monoamine transporter 2 inhibitors. We
Abdelrahman S. Abdalla +4 more
doaj +2 more sources
Co‐Expression of Tardive Dyskinesia and Drug‐Induced Parkinsonism in Rats Chronically Treated With Haloperidol [PDF]
Neuropsychopharmacology ReportsAim We aimed to create a rat model of drug‐induced parkinsonism and tardive dyskinesia by chronic administration of haloperidol and examine the expression of direct and indirect pathway markers in the striatum of the model rats.
Iku Kinoshita +7 more
doaj +2 more sources
Acta Psychiatrica Scandinavica, 1988 ABSTRACT— Tardive dyskinesia (TD) is a syndrome of involuntary movements that develops in predisposed individuals during neuroleptic drug treatment, with an average prevalence of 15%. Neuroleptic (antidopaminergic) drugs are the predominant etiological factor.
J, Gerlach, D E, Casey
+9 more sources
Treatment of tardive dyskinesias with vitamin E: A case series
European Psychiatry, 2023 Introduction Tardive dyskinesia is usually persistent, irreversible involuntary movement of the tongue, lips, face, trunk and extremities in patients taking long-term dopaminergic antagonist drugs.
B. Senol +3 more
doaj +1 more source
Tardive Dyskinesia and Treatment Approaches [PDF]
Psikiyatride Güncel Yaklaşımlar, 2018 Tardive dyskinesia is an iatrogenic movement disorder with an incompletely determined etiology. Involuntary movements can effect oral, lingual, facial, corporal muscles and can be permanent. Tardive dyskinesia is one of the most important side effects of
Mehmet Emin Demirkol +3 more
doaj +1 more source
Geriatric Nursing, 1982 Tardive dyskinesia is now widely recognised as a neurological disorder associated with the administration of antipsychotic drugs. Prevalence is higher among the elderly. The cause is unknown but the hypothesis of hypersensitivity of post-synaptic dopamine receptors is currently generally accepted.
V A, Portnoi, J E, Johnson
+9 more sources
Schizophrenia Bulletin, 1993 Neuroleptic-induced tardive dyskinesia (TD) continues to be a serious problem in the psychopharmacology of schizophrenia. The overall mean prevalence of TD among chronically neuroleptic-treated patients is approximately 24 percent. The annual incidence in younger adults is 4 to 5 percent. Aging is a major risk factor for TD.
D V, Jeste, M P, Caligiuri
openaire +2 more sources
Metoclopramide in Gastroparesis: Its Mechanism of Action and Safety Profile
Gastrointestinal Disorders, 2023 Metoclopramide has been the cornerstone of gastroparesis management for the past 40 years as it is the only FDA-approved medication for gastroparesis. Other medications such as erythromycin and domperidone have been used off-label with variable efficacy.
M Ammar Kalas +4 more
doaj +1 more source
Metoclopramide Neurological Side Effects Screening; A Pharmacovigilence Study in Romanian Community Pharmacies [PDF]
, 2015 Background. Metoclopramide is a pharmacological agent frequently used in therapy against nausea and vomiting that can occur in indigestion, motion sickness, gastric ulcer, pyloric spasm and after surgery as a side effect of some anesthetics.
Junghină, Adrian +4 more
core +4 more sources
Бюллетень сибирской медицины, 2015 The purpose of the present work was to study the clinical features and risk factors of tardive dyskinesia among the schizophrenia patients who durably receive the antipsychotic therapy.
Ye. G. Kornetova +4 more
doaj +1 more source